LLS Phone Education Program for October: T-Cell, MALT, and WM

Here are the following details regarding the next scheduled free telephone education program presented by the Leukemia & Lymphoma Society:

Details

Title: Treating Uncommon Lymphomas: Dialogue With an Expert on T-Cell, MALT, and Waldenström Macroglobulinemia (WM)

Date: Wednesday October 14, 2009
Time: 12:00 Eastern time

Features

Registration is required but participation is free. You can register HERE or you can register by phone by calling (800) 390-3634.

This particular program will feature Richard R. Furman, MD, Assistant Professor, Center for Lymphoma and Myeloma, Division of Hematology and Oncology, Weill Medical College of Cornell University , New York, NY.

Participants can ask Dr. Furman questions during the program.

Sponsors

The Leukemia & Lymphoma Society
Allos Therapeutics, Inc.
Eisai Inc

Additional information

Call the information Resource Center at (800) 955-4572 or send an email to infocenter@lls.org.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap